GlassScriptPhysician profile
Bradley J Barnett
NPI 1619925849
$1,542.92
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $180 · 2021: $651 · 2022: $479.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $269.95 | 2021-2022 | |
| Glaxosmithkline, LLC. | $241.73 | 2019-2022 | |
| Abbott Laboratories | $195.98 | 2021-2022 | |
| Amgen INC. | $131.99 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $96.45 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $84.84 | 2021-2022 | |
| Pfizer INC. | $75.77 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $59.47 | 2020-2022 | |
| Esperion Therapeutics, INC. | $57.58 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $52.56 | 2019 | |
| Amarin Pharma, INC. | $51.44 | 2021 | |
| Radius Health, INC. | $40.12 | 2019 | |
| Boston Scientific Corporation | $34.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.08 | 2021 | |
| Bardy Diagnostics, INC. | $28.74 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $15.12 | 2020 | |
| Nevro Corp. | $14.06 | 2021 | |
| Seqirus USA INC | $14.04 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2019 | |
| Ethicon US, LLC | $12.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.